doc. RNDr. Jakub Neradil, Ph.D.
Associate professor, Section of Genetics and Molecular Biology
office: bldg. C13/316
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 6003 |
---|---|
e‑mail: | jneradil@sci.muni.cz |
social and academic networks: |
---|
Total number of publications: 80
2024
-
ASO Author Reflections: The Effect of Local Adjuvants on Cortical Bone Following Intralesional Curettage of Bone Tumors
Annals of Surgical Oncology, year: 2024, volume: 31, edition: 9, DOI
-
Cytogenomika dětských pacientů s Wilmsovým tumorem ve FN Brno
Year: 2024, type: Conference abstract
-
Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits
CELLULAR ONCOLOGY, year: 2024, volume: 47, edition: 6, DOI
-
Micro-CT, Mechanical, and Histological Examination of the Effect of Local Adjuvants on Porcine Cortical Bone Following Intralesional Curettage of Bone Tumors
Annals of Surgical Oncology, year: 2024, volume: 31, edition: 9, DOI
2023
-
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
Cell Death and Disease, year: 2023, volume: 14, edition: 11, DOI
2022
-
Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma
International Journal of Molecular Sciences, year: 2022, volume: 23, edition: 1, DOI
-
Serotonin limits generation of chromaffin cells during adrenal organ development
Nature Communications, year: 2022, volume: 13, edition: 1, DOI
-
Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
Frontiers in Pharmacology, year: 2022, volume: 13, edition: September, DOI
-
Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors
International Journal of Molecular Sciences, year: 2022, volume: 23, edition: 15, DOI
2021
-
New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling
Cancers, year: 2021, volume: 13, edition: 14, DOI